Clinical Trials List
Protocol NumberBR-101801-CT-101
2022-03-01 - 2022-08-04
Phase I/II
Terminated3
-
Trial Applicant
IQVIA RDS Taiwan Ltd.
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2025/08/20
Investigators and Locations
Co-Principal Investigator
- 顏志傑 Division of Hematology & Oncology
- Chun-Hui Lee Division of Hematology & Oncology
- Ya-Ping Chen Division of General Internal Medicine
- Ya-Ting Hsu Division of General Internal Medicine
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
- 田豐銘 Division of General Internal Medicine
- Shang-Ju Wu Division of General Internal Medicine
- Chien-Chin Lin Division of Others -
- CHENG-HONG TSAI Division of General Internal Medicine
- KUAN-YIN KO Division of Nuclear Medicine
- MING YAO Division of General Internal Medicine
- Tai-Chung Huang Division of General Internal Medicine
- Chieh-Lung Cheng Division of General Internal Medicine
- - - Division of General Internal Medicine
- Huai-Hsuan Huang Division of General Internal Medicine
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
- 吳宜穎 Division of Hematology & Oncology
- 賴學緯 Division of Hematology & Oncology
- 張平穎 Division of Hematology & Oncology
- 葉人華 Division of Hematology & Oncology
- 陳義丰 Division of Nuclear Medicine
- 戴明燊 Division of Hematology & Oncology
- 陳佳宏 Division of Hematology & Oncology
- 蔡文銓 Division of Others
- 何景良 Division of Hematology & Oncology
- 黃子權 Division of Hematology & Oncology
- 李卓豪 Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Terminated
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
8 participants
-
Global
65 participants
